In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Xtandi (enzalutamide), produced by biopharma company Medivation and Japanese drug major Astellas Pharma is to be the sales-leading agent across the world’s major market for prostate cancer, earning $3.4 billion sales in 2023, according to research by biopharma data and analysis firm Decision Resources Group. 31 October 2014
Netherlands-based company Qiagen has announced a master collaboration agreement with Japanese drug major Astellas Pharma. Financial terms of the accord were not disclosed. 29 October 2014
US pharma major Bristol-Myers Squibb has entered into an agreement that provides it with the exclusive option to acquire UK-based F-star Alpha Ltd, and gain worldwide rights to its lead asset, FS102. 28 October 2014
Elderly people in the UK with Myelodysplastic Syndromes (MDS), a rare form of blood cancer, are not being managed according to official treatment guidelines resulting in substandard care, according to a new Call to Action launched this week by the MDS UK Patient Support Group and Leukaemia CARE with support from US biotech major Celgene. 28 October 2014
US pharma giant Merck & Co (NYSE: MRK) posted third-quarter 2014 financial results today, showing that sales for the period fell 4% to $10.56 billion, shy of Wall Street expectations of $10.67 billion. 27 October 2014
Just seven months after the collaboration was announced, Japan’s largest drugmaker Takeda Pharmaceutical has opted for commercial rights to the first Fleximer antibody-drug conjugate (ADC) arising from its partnership with privately-held biotech firm Mersana Therapeutics. 27 October 2014
Blood-related cancer specialist CTI BioPharma has acquired the worldwide rights to tosedostat through transactions with its originator, Vernalis, and Chroma, through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America. 27 October 2014
The European Medicines Agency has concluded its review of the benefits and risks of Iclusig (ponatinib), a treatment of leukemia, and has recommended strengthened warnings in the product information aimed at minimizing the risk of blood clots and blockages in the arteries. 24 October 2014
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of Anglo-Swedish pharma major AstraZeneca’s Lynparza (olaparib). 24 October 2014
China’s WuXi PharmaTech has entered into a collaboration with USA-based Foundation Medicine to offer the latter’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China. 24 October 2014
Danish biotech company Genmab has reached the fourth milestone in its daratumumab collaboration with US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen. 24 October 2014
The US District Court for the District of Delaware has upheld US pharma giant Pfizer’s basic patent and the L-malate salt patent covering Sutent (sunitinib malate) capsules. 23 October 2014
Sutro Biopharma today announced it has entered into a strategic collaboration and option agreement with US biotech major Celgene to discover and develop multi-specific antibodies and antibody drug conjugates (ADCs). 23 October 2014
US pharma major Eli Lilly and privately-held Canadian biotech firm Zymeworks have expanded their existing cancer immune therapy licensing and collaboration agreement. 23 October 2014
French drugmaker Ipsen has entered into an accord with Lexicon Pharmaceuticals to commercialize the US drug developer’s telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. 22 October 2014
Clinical-stage oncology biotech company PhosImmune has entered into a license and collaboration agreement with Pure MHC, a platform technology company specializing in disease-specific target identification for cancer, infectious and autoimmune diseases. 22 October 2014
The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending UK pharma giant GlaxoSmithKline’s Tafinlar (dabrafenib for the treatment of melanoma which has spread or cannot be completely removed by surgery, and which tests positive for the BRAF V600 mutation. 22 October 2014